Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 1.00 |
| ▸ | HTR2A | P28223 | 18/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6605773 | 0.89 | HTR2C (0.80) | HTR2CHTR2AHTR2B | |
| Fumaric Acid SCHEMBL6607435 | 0.89 | HTR2C (0.80) | HTR2CHTR2AHTR2B | |
| SCHEMBL905799 | 0.89 | HTR2C (1.00) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL905906 | 0.79 | HTR2A (0.66) | HTR2CHTR2AHTR2B | |
| Fumaric Acid SCHEMBL6604972 | 0.79 | HTR2C (0.80) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| Fumaric Acid SCHEMBL6604968 | 0.79 | HTR2C (0.80) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| SCHEMBL25296051 | 0.76 | HTR2C (0.65) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| SCHEMBL24110209 | 0.76 | HTR2C (0.65) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| SCHEMBL6604236 | 0.75 | HTR2A (0.60) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| SCHEMBL6603614 | 0.75 | HTR2C (1.00) | HTR2CHTR2AHTR2BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109809-B1 | PYRROLOQUINOLINES FOR TREATMENT OF OBESITY | CEREBRUS PHARM LTD (GB) | 2004-11-17 | — | — | EP | claimed |
| US-6365598-B1 | FOR THERAPY AND PROPHYLAXIS OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS; AND SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2002-04-02 | — | — | US | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| CN-1780612-B | Treatment of incontinence with 5HT2C agonists. | PFIZER | 2010-12-01 | — | — | CN | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| CN-1780612-A | Treatment of incontinence with 5HT2C agonists. | PFIZER (US) | 2006-05-31 | — | — | CN | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| EP-1109809-B1 | PYRROLOQUINOLINES FOR TREATMENT OF OBESITY | CEREBRUS PHARM LTD (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| US-6365598-B1 | FOR THERAPY AND PROPHYLAXIS OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS; AND SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2002-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2A 6/4885HTR2B 10/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2A 6/4885HTR2B 10/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2A 6/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.